Most people who see a Wegovy savings card do not qualify for the full advertised discount. The largest reduction generally assumes you already have commercial insurance that covers Wegovy, with the card lowering the copay that remains. People on Medicare or Medicaid are usually excluded, and cash payers with no coverage rarely get the headline number. What you pay is set by your insurance status first and the coupon second, not the other way around.
What is the Wegovy savings card actually built for?
The commercial copay card is designed for one situation: a person with private, employer, or marketplace insurance whose plan already lists Wegovy as a covered drug. In that case the card caps the monthly copay at a set amount for eligible fills. It is a copay assistance tool, not a standalone discount that works for everyone who walks up to a pharmacy counter.
That single design choice explains most of the confusion. The advertised figure looks like a universal price. It is closer to a best-case outcome for a specific insured shopper. Read the eligibility fine print before you assume it applies to you, because the conditions do most of the work of deciding who benefits.
Who is excluded, and why?
Government insurance is the big exclusion. Federal rules generally bar manufacturer copay cards for people enrolled in Medicare, Medicaid, TRICARE, or similar programs. So if you are on Medicare Part D, the commercial Wegovy card almost certainly will not work for you, even if a pharmacist scans it. Part D has also historically been restricted from covering drugs used purely for weight loss, which compounds the problem for older adults.
The other quiet exclusion is category coverage. Many commercial plans exclude anti-obesity medication as a benefit class. When that happens, the card’s largest discount often does not apply, because it was written to reduce a covered copay rather than replace a missing benefit. The 2025 clinical practice guideline update for obesity pharmacotherapy is direct about how uneven access remains despite strong efficacy data; that unevenness is largely a coverage story, described in the 2025 guideline update.
How do the routes to a Wegovy price compare?
| Route | Who it fits | What sets the number | Main limitation |
|---|---|---|---|
| Commercial savings card | Insured, plan covers Wegovy | Copay cap set by the maker | Excludes government insurance |
| Covered benefit, no card | Insured, coverage but card ineligible | Formulary tier, deductible | Prior authorization common |
| Manufacturer self-pay | Cash payers, no coverage | Fixed monthly cash price | Refill and enrollment conditions |
| Compounded semaglutide | Cash payers via telehealth | Pharmacy and provider pricing | Not an FDA-approved product |
What if you have no insurance at all?
If you have no coverage, the commercial copay card is mostly beside the point. The route built for you is the manufacturer self-pay program, which sets a flat monthly cash price for Wegovy without a plan in the loop. It undercuts the list price meaningfully, though it comes with conditions on refill timing and staying enrolled, so the sustainable monthly figure matters more than the first month.
Cash payers also compare compounded semaglutide, and it is worth being precise about what that is. Compounded semaglutide is prepared by a compounding pharmacy and is not an FDA-approved product. It has not been through the review that produced Wegovy’s trial evidence, and the FDA has flagged safety and dosing concerns tied to versions sold outside the approved supply, documented in its notice on medications containing semaglutide. What compounded routes offer is a predictable cash price; what they give up is that regulatory assurance. That is a real trade, not a technicality.
Supervised telehealth practices are where much of this cash-pay activity now lives. Named options include Ro, Hims and Hers, Henry Meds, and NovoCare on the brand side, alongside compounding-focused services. For a side-by-side of coupon eligibility against flat self-pay pricing, FormBlends’ guide is one physician-supervised resource that lays the options out; prescribing there is handled by a licensed clinician rather than sold as a product off a shelf.
Does the card cover Ozempic or other semaglutide products?
No, and this trips up a lot of shoppers. Ozempic and Wegovy both contain semaglutide, but they are separate products with separate labels and separate assistance programs. Ozempic is labeled for type 2 diabetes; Wegovy is labeled for chronic weight management. Their prescribing information differs on approved dosing and indications, which you can confirm in the Wegovy label and the Ozempic label. A Wegovy savings card does not carry over to Ozempic, and coverage rules diverge because a diabetes indication and a weight indication are treated differently by many plans.
Is the medication worth the paperwork?
For many people the efficacy data supports the effort, and the honest answer depends on whether coverage exists. In STEP 3, semaglutide combined with intensive behavioral therapy produced substantial weight loss, reported in the STEP 3 trial. STEP 8 compared it head-to-head against daily liraglutide and favored semaglutide, detailed in the STEP 8 trial. Two other findings matter for cost planning: STEP 4 showed that continuing treatment maintains the loss, while stopping tends to reverse it, and a STEP 1 extension found meaningful weight regain after withdrawal. Those results, in the STEP 4 trial and the STEP 1 extension, mean this is likely an ongoing expense, not a one-time course.
So the card question is really a durability question. A discount that vanishes after a few fills is not much help for a medication most people take for years. What is not worth it is chasing a coupon before confirming whether the plan covers the category, because that single fact decides which route even applies. Whether treatment is indicated at all rests on a clinical assessment of obesity, not a body mass index number alone, a distinction argued in the 2025 work on the definition of clinical obesity.
Key takeaways
- The commercial Wegovy savings card mostly helps people who already have covered insurance.
- Medicare, Medicaid, and other government plans are generally excluded from the card.
- Cash payers use manufacturer self-pay or compounded routes, not the copay card.
- Compounded semaglutide is not FDA-approved, whatever its price advantage.
- Confirm category coverage before comparing any coupon, because it decides the route.
See also: Five Lakes Law Group: Services and Contact
Frequently asked questions
Who qualifies for the Wegovy savings card?
Mainly people with commercial insurance. The largest advertised reduction generally assumes a commercial plan that already covers Wegovy, with the card trimming the copay. People on Medicare, Medicaid, or other government insurance are usually excluded.
Can I use a Wegovy coupon with no insurance?
Not the full commercial copay card. That program assumes existing commercial coverage. Cash payers are steered instead toward the manufacturer self-pay program, which sets a fixed monthly price without a plan involved.
Why is my out-of-pocket cost higher than the advertised number?
The headline figure usually assumes your plan covers Wegovy and applies a monthly cap. If your plan excludes weight management or has not met the card conditions, the discount shrinks or does not apply at all.
Does the savings card cover Ozempic too?
No. Ozempic and Wegovy both contain semaglutide, but they are separate products with separate programs. A Wegovy savings card does not transfer to Ozempic, and coverage rules differ because one is labeled for weight management and the other for type 2 diabetes.
Is compounded semaglutide a cheaper version of Wegovy?
No. Compounded semaglutide is prepared by a compounding pharmacy and is not an FDA-approved product. It may use the same active molecule, but it has not gone through the approval process behind Wegovy’s published trials.
